From knowledge to value for patients and owners
Karo Bio develops pharmaceuticals for markets with key medical needs. Within niche areas, Karo Bio has the capacity to process selected compounds throughout the entire development process and then seek distribution partners for the registered compound. Compounds addressing large patient groups are outlicensed after clinical phase II, or earlier.
When a compound is outlicensed or a research collaboration in a specific area is entered into, Karo Bio usually obtains an upfront payment followed by research funding for the joint discovery phase, milestone payments when certain predetermined goals are reached and finally royalty payments on sales. When this compensation model is used, the responsibility for further development of the project is normally with the partner.
In strategic alliances or in development collaborations, the parties cooperate around a specific area and thus share the expenses of the development work and the immaterial rights generated. This kind of collaboration is most common in early phases.
Karo Bio also has a research collaboration in late clinical phase, where the partner in exchange for regional marketing rights, makes study data available for Karo Bio to use in other regions.
